Roth Capital weighs in on Pozen (POZN -15%) after the FDA asked drug developer to provide...


Roth Capital weighs in on Pozen (POZN -15%) after the FDA asked drug developer to provide additional information about its potentially less gastro-erosive aspirin, saying the shares should be bought on the weakness. Roth thinks the company will still be able to file an application for the drug with the FDA by the end of the year. The firm maintains a $10 target and Buy rating on the stock.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs